国产重组人类促红细胞生成素防治早产儿贫血的临床效果研究

Evaluation of clinical efficacy of domestic made recombinant human erythropoietin in preventing and treating anemia in preterm infants

为评价国产重组人类促红细胞生成素 (rhEPO)防治早产儿贫血的效果和安全性 ,将40例胎龄≤34周的早产儿随机分为治疗组及对照组各20例。治疗组予国产rhEPO750IU/(kg·w) ,每周分3次皮下注射 ,用药6周 ;对照组未用rhEPO ;两组早产儿均口服铁剂。结果显示治疗组用药后血清促红细胞生成素水平显著高于对照组 (P<0.01) ;治疗组血红蛋白、红细胞压积比、网织红细胞均显著高于对照组 (P<0.01) ;血清铁蛋白水平在用药后治疗组明显低于对照组 (P<0.01) ;治疗组输血率较对照组明显减少 (P<0.05) ;治疗组体重增长指标高于对照组 (P<0.05)。研究提示 ,国产rhEPO能有效防治早产儿贫血 ,且用药安全 。

To evaluate the clinical efficacy and safety of domestic made recombinant human erythropoietin(rhEPO) in preventing and treating anemia for preterms,forty infants (gestational age<34 weeks) were randomly assigned to either rhEPO_treated group(treatings) or control group(controls).Treatings were given domestic rhEPO subcutaneously(750 IU/kg·w,three times weekly for 6 weeks)started at the age of 1 week.Controls received no rhEPO.All infants received oraliron.The results showed that serum rhEPO level in treatings was significantly higher than that in controls(P<0.01).Hig_her levels of hemoglobin,hematocrit and reticulocyte counts were markedly noted in treatings.Serum ferritin level was significantly lower in treatings compared to that in controls(P<0.05).The frequency of transfusion was lower in treatings(P<0.01).The treatings had a greater weight gain during theraputic time(P<0.01).It is concluded that domestic made rhEPO is safe and efficient in preventing and treating anemia for prematurity.